Spondyloarthritis & psoriatic arthritis
C-reactive protein thresholds for discriminating active disease in psoriatic arthritis may be different in early versus established disease
Authors' conclusion
Our results suggest the adoption of lower than standard CRP cut-off values for a better assessment of PsA in clinical practice.
Study context
- Population
- Patients with psoriatic arthritis (PsA), early-onset (not exposed to high-impact therapies) and established (under biologics and oral targeted therapies)
- Participants
- 345 patients
- Comparison
- C-reactive protein (CRP) thresholds for discriminating active disease in early vs established PsA
- Cohort In = 215
- Cohort IIn = 130
- Outcome
- CRP thresholds discriminating active disease (Youden index; AUROC)
Methodological detailstwo cohorts (recent-onset and established PsA), Youden index, area under the receiver-operating characteristic (AUROC)
- Two cohorts (recent-onset and established PsA)
- Youden index
- AUROC
Performance
As reported in the abstract
CRP thresholds discriminating active disease
| Test or model | CRP threshold | AUROC | OR | p |
|---|---|---|---|---|
| Cohort II | around 0.20 mg/dl | 0.71 | 4.7 | p<0.001 |
Cohort II
CRP thresholdaround 0.20 mg/dl
AUROC0.71
OR4.7
pp<0.001
Further findings
- CRP threshold for active disease, cohort II patients not exposed to anti-TNF drugs (subgroup)
- ≥0.22 mg/dl · CRP threshold · AUROC 0.86
Original publication
C-reactive protein thresholds for discriminating active disease in psoriatic arthritis may be different in early versus established disease. Clin Exp Rheumatol. Published 4 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →